Oral treatment for hepatitis B gets approval in United StatesBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7165.1034b (Published 17 October 1998) Cite this as: BMJ 1998;317:1034
- Deborah Josefson
- San Francisco
The first oral treatment for hepatitis B infection has just received approval from an advisory panel to the Food and Drug Administration in the United States. Lamivudine (Epivir), also known as 3TC, is a nucleoside reverse transcriptase inhibitor that blocks viral replication and is currently used to combat AIDS.
Hepatitis B virus infects about 350 million people worldwide. No cure exists, and current strategies rely on vaccination or treatment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial